Biotechnology
Compare Stocks
2 / 10Stock Comparison
ICU vs STE
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
ICU vs STE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Medical - Devices |
| Market Cap | $29M | $21.00B |
| Revenue (TTM) | $881K | $5.83B |
| Net Income (TTM) | $-14M | $708M |
| Gross Margin | 95.3% | 44.1% |
| Operating Margin | -15.8% | 17.2% |
| Forward P/E | — | 21.0x |
| Total Debt | $574K | $2.20B |
| Cash & Equiv. | $2M | $172M |
ICU vs STE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| SeaStar Medical Hol… (ICU) | 100 | 1.9 | -98.1% |
| STERIS plc (STE) | 100 | 128.5 | +28.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ICU vs STE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ICU is the clearest fit if your priority is growth exposure.
- Rev growth 12.0%, EPS growth 78.1%
- 12.0% revenue growth vs STE's 6.2%
- +291.9% vs STE's -3.9%
STE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 14 yrs, beta 0.69, yield 1.0%
- 220.0% 10Y total return vs ICU's -98.1%
- Lower volatility, beta 0.69, Low D/E 33.3%, current ratio 1.96x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.0% revenue growth vs STE's 6.2% | |
| Quality / Margins | 12.1% margin vs ICU's -15.5% | |
| Stability / Safety | Beta 0.69 vs ICU's 1.06 | |
| Dividends | 1.0% yield; 14-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +291.9% vs STE's -3.9% | |
| Efficiency (ROA) | 6.7% ROA vs ICU's -88.0% |
ICU vs STE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ICU vs STE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — ICU and STE each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
STE is the larger business by revenue, generating $5.8B annually — 6615.2x ICU's $881,000. STE is the more profitable business, keeping 12.1% of every revenue dollar as net income compared to ICU's -15.5%. On growth, ICU holds the edge at +169.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $881,000 | $5.8B |
| EBITDAEarnings before interest/tax | -$14M | $1.4B |
| Net IncomeAfter-tax profit | -$14M | $708M |
| Free Cash FlowCash after capex | -$14M | $917M |
| Gross MarginGross profit ÷ Revenue | +95.3% | +44.1% |
| Operating MarginEBIT ÷ Revenue | -15.8% | +17.2% |
| Net MarginNet income ÷ Revenue | -15.5% | +12.1% |
| FCF MarginFCF ÷ Revenue | -16.1% | +15.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +169.1% | +9.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +88.2% | +12.0% |
Valuation Metrics
Evenly matched — ICU and STE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $29M | $21.0B |
| Enterprise ValueMkt cap + debt − cash | $28M | $23.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.73x | 34.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.95x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.35x |
| EV / EBITDAEnterprise value multiple | — | 17.15x |
| Price / SalesMarket cap ÷ Revenue | 215.18x | 3.85x |
| Price / BookPrice ÷ Book value/share | — | 3.20x |
| Price / FCFMarket cap ÷ FCF | — | 27.00x |
Profitability & Efficiency
STE leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
STE delivers a 9.9% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-119 for ICU. On the Piotroski fundamental quality scale (0–9), STE scores 8/9 vs ICU's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -119.2% | +9.9% |
| ROA (TTM)Return on assets | -88.0% | +6.7% |
| ROICReturn on invested capital | — | +7.2% |
| ROCEReturn on capital employed | — | +9.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 |
| Debt / EquityFinancial leverage | — | 0.33x |
| Net DebtTotal debt minus cash | -$1M | $2.0B |
| Cash & Equiv.Liquid assets | $2M | $172M |
| Total DebtShort + long-term debt | $574,000 | $2.2B |
| Interest CoverageEBIT ÷ Interest expense | -209.88x | 15.94x |
Total Returns (Dividends Reinvested)
STE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in STE five years ago would be worth $10,588 today (with dividends reinvested), compared to $189 for ICU. Over the past 12 months, ICU leads with a +291.9% total return vs STE's -3.9%. The 3-year compound annual growth rate (CAGR) favors STE at 5.3% vs ICU's -53.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +84.7% | -14.3% |
| 1-Year ReturnPast 12 months | +291.9% | -3.9% |
| 3-Year ReturnCumulative with dividends | -90.1% | +16.6% |
| 5-Year ReturnCumulative with dividends | -98.1% | +5.9% |
| 10-Year ReturnCumulative with dividends | -98.1% | +220.0% |
| CAGR (3Y)Annualised 3-year return | -53.7% | +5.3% |
Risk & Volatility
Evenly matched — ICU and STE each lead in 1 of 2 comparable metrics.
Risk & Volatility
STE is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than ICU's 1.06 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICU currently trades 95.6% from its 52-week high vs STE's 79.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.06x | 0.69x |
| 52-Week HighHighest price in past year | $5.08 | $269.44 |
| 52-Week LowLowest price in past year | $0.22 | $204.81 |
| % of 52W HighCurrent price vs 52-week peak | +95.6% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 65.7 | 41.2 |
| Avg Volume (50D)Average daily shares traded | 150K | 710K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
STE is the only dividend payer here at 1.04% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $256.67 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | +1.0% |
| Dividend StreakConsecutive years of raises | — | 14 |
| Dividend / ShareAnnual DPS | — | $2.22 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.0% |
STE leads in 2 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 3 categories are tied.
ICU vs STE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ICU or STE a better buy right now?
STERIS plc (STE) offers the better valuation at 34.
5x trailing P/E (21. 0x forward), making it the more compelling value choice. Analysts rate STERIS plc (STE) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ICU or STE?
Over the past 5 years, STERIS plc (STE) delivered a total return of +5.
9%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: STE returned +220. 0% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ICU or STE?
By beta (market sensitivity over 5 years), STERIS plc (STE) is the lower-risk stock at 0.
69β versus SeaStar Medical Holding Corporation's 1. 06β — meaning ICU is approximately 53% more volatile than STE relative to the S&P 500.
04Which is growing faster — ICU or STE?
On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78.
1% year-over-year, compared to 62. 7% for STERIS plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ICU or STE?
STERIS plc (STE) is the more profitable company, earning 11.
3% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 11. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STE leads at 15. 9% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ICU or STE?
In this comparison, STE (1.
0% yield) pays a dividend. ICU does not pay a meaningful dividend and should not be held primarily for income.
07Is ICU or STE better for a retirement portfolio?
For long-horizon retirement investors, STERIS plc (STE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
69), 1. 0% yield, +220. 0% 10Y return). Both have compounded well over 10 years (STE: +220. 0%, ICU: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ICU and STE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
STE pays a dividend while ICU does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.